The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; none of the 23 sources its claims cite is checked for support yet.
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Open accessAbstract
BACKGROUND: Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally. OBJECTIVE: To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures. METHODS: A total of 819 subjects (229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials. RESULTS: The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD. Nonmemory cognitive measures were only minimally impaired in the subjects with MCI. The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year. Approximately 50% of the subjects with MCI were on antidementia therapies. There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3. Baseline CSF measures of Abeta-42 separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures. CONCLUSION: The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics. The 12-month progression rate of MCI was as predicted, and the CSF measures heralded progression of clinical measures over 12 months.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This ADNI clinical characterization paper reports baseline and 12-month clinical, cognitive, and CSF biomarker data for 819 participants: 229 cognitively normal, 398 with MCI, and 192 with mild AD. It shows expected group differences at baseline, a 16.5% 12-month MCI-to-AD progression rate, and baseline CSF Aβ-42 predicting 12-month cognitive change in normal and MCI groups.
Key findings
- At baseline, ADAS-Cog total scores were 6.2 ± 2.9 in controls, 11.5 ± 4.4 in MCI, and 18.6 ± 6.3 in AD (p < 0.001); MCI subjects were most impaired on memory items and only mildly impaired in nonmemory domains.
- Over 12 months, 64 of 398 MCI subjects progressed to AD, a rate of 16.5% (95% CI 11.9%–20.5%); normal controls progressed to MCI at an estimated 1.4% (95% CI 0%–3.2%).
- ADAS-Cog 12-month change was −0.5 ± 3.0 in controls, 1.1 ± 4.4 in MCI, and 4.3 ± 6.6 in AD (p < 0.001).
- Baseline CSF Aβ-42 decreased across groups (controls 206 ± 5, MCI 164 ± 4, AD 143 ± 4 pg/mL; p < 0.001), and higher baseline Aβ-42 was associated with better ADAS-Cog performance and smaller 12-month change in normal subjects and MCI.
Methods
- Multicenter ADNI cohort of 819 subjects aged 55–90 enrolled at baseline and classified as cognitively normal, MCI, or mild AD using standard clinical, cognitive, and functional criteria; subjects were followed for 12 months with cognitive and functional measures, MRI/PET in subsets, and lumbar puncture in a minimum of 20% per site.
- Baseline group comparisons used nonparametric tests (Kruskal-Wallis) with Hochberg multiple comparisons and exact tests for proportions; 12-month change was summarized as conversion proportion, baseline-to-12-month mean or percent difference, and rate per year from mixed-effects regression models.
- Annual conversion rates were estimated using a hybrid interval-censored method; CSF Aβ-42 was related to diagnosis, ADAS-Cog performance, and 12-month ADAS-Cog change.
Limitations
- The paper states that a 12-month change period is not sufficient to draw conclusions about the likelihood of clinical change, and that the ADNI cohort likely does not represent “typical” community subjects because participants were more highly educated, mostly white, and had a high proportion of APOE4 carriers in the MCI and AD groups.
- The paper also states that the MCI criteria required a stringent degree of memory impairment, so these subjects were likely further along the clinical spectrum and more likely to progress than less-impaired MCI subjects.
- Evident from the text: CSF analyses were limited to subsets (baseline n = 114 controls, 199 MCI, 102 AD), and some subjects lacked 12-month follow-up diagnoses (17 controls and 41 MCI subjects), which limits interpretation of conversion and biomarker results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
53 Own result · 8 Sources not found · 8 Own interpretation · 5 No basis given · 3 Not checked yet · 3 Own method
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“successfully predicted the 12-month change in cognitive measures.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plaincorrelationaln = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but they looked more like the AD group for change in digit span, category fluency, and trail making”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nonmemory cognitive measures were only minimally impaired in the subjects with MCI.”
- Also stated in: § RESULTS Baseline characteristics. · hedged
“The neuropsychological battery indicated that, in general, subjects with MCI were more impaired than controls on the memory items and were only mildly impaired in nonmemory domains (table 3).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS Baseline characteristics. · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The sub-jects with AD were impaired in virtually all of the cognitive areas tested.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These scores indicated, however, that the subjects with MCI gained most of their error points on memory items.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline CSF measures of A-42 separated the 3 groups as expected”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plaincorrelationaln = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The next greatest area of impairment for the subjects with MCI resulted from the executive function domain.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The subjects with MCI also remained relatively stable as a group, and the subjects with mild AD showed a decline on most of these measures.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The interaction of A-42 and time also had a significant effect on ADAS-Cog scores in subjects with MCI ( p ϭ 0.00), but not in normal subjects.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 14
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CDR sum of the boxes essentially did not change in the normal control group (0.1) and increased by approximately 0.7 points in the subjects with MCI and 1.5 points in the subjects with AD ( p Ͻ 0.001).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD.”
- Also stated in: § RESULTS Baseline characteristics. · hedged
“These scores indicated, however, that the subjects with MCI gained most of their error points on memory items.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS Baseline characteristics. · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In general, the normal group stayed nearly the same, and the AD group worsened significantly compared to the normal controls.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and more like the normal controls for the clock test and global CDR.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, subjects with MCI had a mean total Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) score of 11.5, while the normal control subjects had a score of 6.2 and the subjects with mild AD had a score of 18.7 ( p Ͻ 0.001, table 3).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“cholinesterase inhibitors-normal controls 0%, subjects with MCI 43.7%, subjects with AD 84.9%”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 819 subjects were recruited and received a baseline evaluation as part of the ADNI study.”
- Also stated in: § RESULTS Baseline characteristics. · plain
“There were 229 normal control subjects, 398 subjects with MCI, and 192 subjects with mild AD enrolled.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS Baseline characteristics. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The estimated premorbid verbal IQ of these subjects was quite high, at almost 120 for the normal control subjects, 116 for the subjects with MCI, and 114 for the subjects with AD.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
hedgedn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In all cases except the Hachinski Scale and Geriatric Depression Scale, the mean scores for the 3 groups differed significantly at p Ͻ 0.001, with normal controls performing best, subjects with AD worst, and subjects with MCI in the middle.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The MCI group was more variable; in most cases they worsened more than the normal group but not as much as the AD group”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Approximately 50% of the subjects with MCI were on antidementia therapies.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most of the subjects in the study were white, and this was approximately equivalent across the groups.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in table 2, the mean age of the 3 groups was equivalent at approximately 75 years.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“there were more men than women in the MCI group (64.6% men vs 35.4% women).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 398- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“There was somewhat less variability on the global measures, while some of the individual neuropsychological tests such as the AVLT showed considerable variability among the subjects despite relatively modest mean group changes.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“CSF A-42 levels were assessed at baseline and were correlated with clinical diagnoses, performance on the ADAS-Cog, and changes in performance on the ADAS-Cog over 1 year (table 3).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Delayed recall improved by 5.3% in the normal control group and declined by 4.8% in the subjects with MCI and 7.2% in the subjects with AD.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“As such, the baseline characteristics of the subjects indicated that the 3 groups were generally well educated, intelligent, and mostly white, and perform in a fashion similar to subjects recruited for typical clinical trials.[25][26][27][28]”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CSF A-42 data correlated with the diagnostic groups in the expected fashion with levels being lower in the subjects with MCI than in the normal subjects.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: CSF Aβ-42 level is a valid biomarker of Alzheimer's disease pathology and progression.
None of the sources cited for this claim have been checked yet.
In the paper
“They tend to be more highly educated and the proportion of APOE4 carriers was quite high in the MCI and AD groups but is consistent with subjects recruited for clinical trials.25”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“On the memory measures such as the AVLT, there was virtually no change across 12 months in learning in the normal control group with a decreased learning of 1.3 items in the subjects with MCI and 3.7 fewer items learned in the AD group.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“An additional 8 subjects with MCI reverted to a normal classification over that interval, and 41 did not have a follow-up diagnosis.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plainn = 398- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“may allow detection of the neurodegenerative process at an earlier point in the spectrum”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [6]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [7]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [8]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All hypothesis tests were 2-sided at level 0.05, and models were validated both graphically and analytically.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Data analysis.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Most investigators believe that Alzheimer disease (AD) is a slowly evolving process that likely begins years to decades before the clinical symptoms are manifest.1”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [1]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A 12month change period is not a sufficient amount of time to draw conclusions regarding the likelihood of clinical change.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“has been a target for clinical trials.[2][3][4][5]”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [2]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [5]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The diagnostic conversions over the 12-month period must be viewed with some caution.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This might be a useful technique to reduce the numbers of subjects used in clinical trials to detect a clinical effect of therapeutic interventions.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
- Rests on an assumption: CSF Aβ-42 level is a valid biomarker of Alzheimer's disease pathology and progression.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Mild cognitive impairment (MCI) represents an attempt to characterize subjects at an early clinical phase”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [2]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [5]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Not matched
The paper relies on this without support.
The expected 12-month progression rate for MCI was approximately 16.5% per year.
“The 12-month progression rate of MCI was as predicted”
“The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year.”
The paper relies on this without support.
The baseline characteristics observed in the recruited cohorts matched the characteristics anticipated for normal, MCI, and AD cohorts.
“The Alzheimer's DiseaseNeuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics.”
The paper relies on this without support.
The MCI subjects have an underlying Alzheimer's disease process that drives clinical progression.
“As such, these subjects were likely further down the clinical spectrum with respect to the underlying AD process such that they would be more likely to progress than subjects with less impairment in the MCI spectrum.”
The paper relies on this without support.
CSF Aβ-42 level is a valid biomarker of Alzheimer's disease pathology and progression.
“The CSF A-42 data correlated with the diagnostic groups in the expected fashion with levels being lower in the subjects with MCI than in the normal subjects.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Another issue is that the vast majority of data from PET and CSF are from selected participants recruited through tertiary care dementia centers [176].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [176]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“Among the 398 subjects with MCI at baseline, 64 progressed to AD at 12 months”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“Table 5 Baseline measures on subjects according to progression status at 1 year Assortment variable Nonprogressors, mean ؎ SD (n ؍ 329) Progressors, mean ؎ SD (n ؍ 69)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“the subjects with mild AD had a score of 18.7”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“ADAS-Cog total 6.2 Ϯ 2.9 11.5 Ϯ 4.4 18.1 18.6 Ϯ 6.3 14.0 Ͻ0.001 a, b, c”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“subjects with MCI (r ϭ Ϫ0.22; 95% CI Ϫ0.035 to Ϫ0.08)”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“95% CI Ϫ0.035 to Ϫ0.08”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“In all cases except the Hachinski Scale and Geriatric Depression Scale, the mean scores for the 3 groups differed significantly at p Ͻ 0.001”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“GDS Score 0.8 Ϯ 1.1 1.6 Ϯ 1.4 7.3 1.7 Ϯ 1.4 0.6 Ͻ0.001 a, b”
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Self-citationRandom-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
VALIDITY OF THE TRAIL MAKING TEST AS AN INDICATOR OF ORGANIC BRAIN DAMAGE
Reitan, R. M. (1958) · Perceptual and Motor Skills · doi:10.2466/pms.1958.8.3.271 · Cited by 8,167
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Self-citationThe Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Gauthier, S. G., Reisberg, ., Zaudig, M., Petersen, R. C., Ritchie, K. A., Broich, K., Belleville, S., Brodaty, H., Bennett, D. A., Chertkow, H. M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 4,094
Self-citationL’examen Clinique en Psychologie
Rubé, P. (1959) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1959.13.4.989 · Cited by 3,299
Cited by
Sorted by citations
Items 201–300 of 2,570
Minimal clinically important difference in Alzheimer's disease: Rapid review
Muir, R. T., Hill, M. D., Black, S. E., & Smith, E. E. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13770 · Cited by 115
Toledo, J. B., Korff, A., Shaw, L. M. J., Trojanowski, J. Q., & Zhang, J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1148-z · Cited by 106
“For the current study, 389 subjects (110 CN, 187 MCI, and 92 AD) in the ADNI-1 cohort [42] had α -syn measured in baseline CSF samples ( .”
Self-citationGenome-wide interaction analysis of pathological hallmarks in Alzheimer's disease
Wang, H., Yang, J., Schneider, J. A., Jager, P. L. D., Bennett, D. A. A., & Zhang, H. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.04.025 · Cited by 100
Sex-specific norms for verbal memory tests may improve diagnostic accuracy of amnestic MCI
Sundermann, E. E., Maki, P. M., Biegon, A. R., Lipton, R. B., Mielke, M. M., Machulda, M. M., Bondi, M. W., & Initiative, A. D. N. (2019) · Neurology · doi:10.1212/wnl.0000000000008467 · Cited by 105
Sex differences in Alzheimer’s-related Tau biomarkers and a mediating effect of testosterone
Sundermann, E. E., Panizzon, M. S., Chen, X., Andrews, M., Galasko, D. R., Banks, S. J., & Initiative, A. D. N. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00310-x · Cited by 110
“The general enrollment inclusion/exclusion criteria for ADNI have been described elsewhere [42].”
Pinaya, W. H. L., Vieira, S., Garcia‐Dias, R., & Mechelli, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815739-8.00010-9 · Cited by 115
Yang, Z., Nasrallah, I. M., Shou, H., Wen, J., Doshi, J. J., Habes, M., Erus, G., Abdulkadir, A., Resnick, S. M., Albert, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26703-z · Cited by 112
Self-citationGenome-wide association analysis of age-at-onset in Alzheimer's disease
Kamboh, M. I., Barmada, M. M., Demirci, F. Y., Minster, R. L., Carrasquillo, M. M., Pankratz, V. S., Younkin, S. G., Saykin, A. J., Initiative, T. A. D. N., Sweet, R. A., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.135 · Cited by 100
Dadar, M., Maranzano, J., Misquitta, K., Anor, C. J., Fonov, V., Tartaglia, M. C., Carmichael, O. T., DeCarli, C. S., & Collins, D. L. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.06.009 · Cited by 100
“Despite the fact that all subjects had to have Hachinski Ischemic Score of less than or equal to 4 as part of the inclusion criteria (Petersen et al., 2010), we found many subjects that had high WMH loads.”
BackgroundA phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment
Levey, A. I., Qiu, D., Zhao, L., Hu, W. T., Duong, D. M., Higginbotham, L. A., Dammer, E. B., Seyfried, N. T., Wingo, T. S., Hales, C. M., et al. (2021) · Brain · doi:10.1093/brain/awab452 · Cited by 106
Predicting brain structural network using functional connectivity
Zhang, L., Wang, L., & Zhu, D. (2022) · Medical Image Analysis · doi:10.1016/j.media.2022.102463 · Cited by 98
“We tested our methods on two datasets: Human Connectome Project (HCP) dataset ( Van Essen et al., 2012 ) and Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset ( Petersen et al., 2010 ).”
Muszyński, P., Groblewska, M., Kulczyńska‐Przybik, A., Kułakowska, A., & Mroczko, B. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170208124324 · Cited by 104
study, T. A. I. B. A. L., Nabais, M. F., Initiative, T. A. D. N., Laws, S. M., Lin, T., Vallerga, C. L., Armstrong, N. J., Blair, I. P., Kwok, J. B., Mather, K. A., et al. (2021) · Genome Biology · doi:10.1186/s13059-021-02275-5 · Cited by 99
A holistic overview of deep learning approach in medical imaging
Yousef, R., Gupta, G., Yousef, N., & Khari, M. (2022) · Multimedia Systems · doi:10.1007/s00530-021-00884-5 · Cited by 112
“[229] Brain MRI 819 patients ChestX-ray14 [129] Lung X-ray 30,000 + patients LIDC-IDRI [230] Lung CT 1018 patients ILD [231] Lung CT 120 patients TCIA Multiple organs with cancer CT, MRI, PET 30.9 million images/37,568 patients DRIVE [232] Eye SLO 400 patients STARE [233] Eye It is used to…”
MethodInfluentialHazarika, R. A., Maji, A. K., Kandar, D., Jasińska, E., Krejčí, P., Leonowicz, Z. M., & Jasiński, M. (2023) · Electronics · doi:10.3390/electronics12030676 · Cited by 110
O’Connor, L. M., O’Connor, B. A., Lim, S. B., Zeng, J., & Lo, C. H. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.06.011 · Cited by 113
Galić, I., Habijan, M., Leventić, H., & Romić, K. (2023) · Electronics · doi:10.3390/electronics12214411 · Cited by 116
TADPOLE Challenge: Prediction of Longitudinal Evolution in Alzheimer's DiseasePreprint
Marinescu, R. V., Oxtoby, N. P., Young, A. L., Bron, E. E., Toga, A. W., Weiner, M. W., Barkhof, F., Fox, N. C., Klein, S., Alexander, D. C., et al. (2018) · arXiv (Cornell University) · doi:10.48550/arxiv.1805.03909 · Cited by 148
Self-citationVasanthakumar, A., Davis, J. W., Idler, K., Waring, J. F., Asque, E., Riley-Gillis, B., Grosskurth, S., Srivastava, G., Kim, S., Nho, K., et al. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00864-y · Cited by 98
“Clinical descriptions of the ADNI cohort have been published [40].”
BackgroundWeise, C. M., Chen, K., Chen, Y., Kuang, X., Savage, C. R., & Reiman, E. M. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.07.016 · Cited by 96
Seshadri, S., Beiser, A., Au, R., Wolf, P. A., Evans, D. A., Wilson, R. S., Petersen, R. C., Knopman, D. S., Rocca, W. A., Kawas, C. H., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.12.002 · Cited by 97
Self-citationNicolas, G., Wallon, D., Charbonnier, C., Quenez, O., Rousseau, S., Richard, A.-C., Rovelet-Lecrux, A., Coutant, S., Le Guennec, K., Bacq, D., et al. (2016) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.173 · Cited by 89
Podhorná, J., Krahnke, T., Shear, M. A., Harrison, J., & Initiative, A. D. N. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0170-5 · Cited by 101
on behalf of the MEMENTO cohort Study Group, Dufouil, C., Dubois, B., Vellas, B. J., Pasquier, F., Blanc, F., Hugon, J., Hanon, O., Dartigues, J., Harston, S., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0288-0 · Cited by 99
Kline, R., Pirraglia, E., Cheng, H. M., Santi, S. D., Li, Y., Haile, M. M., de Leon, M. J., & Bekker, A. (2012) · Anesthesiology · doi:10.1097/aln.0b013e318246ec0b · Cited by 96
Global clinical dementia rating of 0.5 in MCI masks variability related to level of function
Chang, Y., Bondi, M. W., McEvoy, L. K., Fennema‐Notestine, C., Salmon, D. P., Galasko, D. R., Hagler, D. J., Dale, A. M., & Initiative, A. D. N. (2011) · Neurology · doi:10.1212/wnl.0b013e31820ce6a5 · Cited by 95
Popuri, K., Ma, D., Wang, L., & Beg, M. F. (2020) · Human Brain Mapping · doi:10.1002/hbm.25115 · Cited by 96
“…MRI data for training and validating the proposed ensemble-learning based classifier was obtained from 5 publicly available databases, namely ADNI (Petersen et al., 2010), Australian Imaging Bio-markers and Lifestyle Study of Aging (AIBL; Ellis et al., 2009), Open Access Series of Imaging Studies…”
Weigand, S. D., Vemuri, P., Wiste, H. J., Senjem, M. L., Pankratz, V. S., Aisen, P. S., Weiner, M. W., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.08.230 · Cited by 93
Self-citationPredicting the location of human perirhinal cortex, Brodmann's area 35, from MRI
Augustinack, J. C., Huber, K. E., Stevens, A. A., Roy, M., Frosch, M. P., van der Kouwe, A. J. W., Wald, L. L., Leemput, K. V., McKee, A. C., & Fischl, B. R. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.08.071 · Cited by 100
Kandel, B. M., Avants, B., Gee, J. C., McMillan, C. T., Erus, G., Doshi, J. J., Davatzikos, C. A., Wolk, D. A., & Initiative, A. D. N. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.03.001 · Cited by 98
Hippocampal atrophy rates and CSF biomarkers in elderly APOE 2 normal subjects
Chiang, G. C., Insel, P. S., Tosun, D., Schuff, N., Truran-Sacrey, D., Raptentsetsang, S. T., Jack, C. R., Aisen, P. S., Petersen, R. C., Weiner, M. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ffe4d1 · Cited by 94
Self-citationCerebrovascular disease promotes tau pathology in Alzheimer’s disease
Laing, K. K., Simoes, S., Baena-Caldas, G. P., Lao, P. J., Kothiya, M., Igwe, K. C., Chesebro, A. G., Houck, A. L., Pedraza, L., Hernandez, A. I., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa132 · Cited by 94
“Recruitment and diagnostic procedures were described previously (Petersen et al., 2010).”
MethodAssociations of White Matter Hyperintensities with Cognitive Decline: A Longitudinal Study
Wang, Y.-L., Chen, W., Cai, W.-J., Hu, H., Xu, W., Wang, Z.-T., Cao, X.-P., Tan, L., Yu, J.-T., & Initiative, A. D. N. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-191005 · Cited by 92
“The inclusive and exclusive criteria for participants were described in a previous study [11].”
Casanova, R., Whitlow, C. T., Wagner, B., Williamson, J. D., Shumaker, S. A., Maldjian, J. A., & Espeland, M. A. (2011) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2011.00022 · Cited by 93
Tadayon, E., Moret, B., Sprugnoli, G., Monti, L., Pascual‐Leone, Á., Santarnecchi, E., & Initiative, A. D. N. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190706 · Cited by 99
The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease
Hadjichrysanthou, C., Evans, S., Bajaj, S., Siakallis, L. C., McRae-McKee, K., de Wolf, F., Anderson, R. M., & Initiative, T. A. D. N. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00636-z · Cited by 86
“Previous work has mainly focused on the description of the dynamics within different clinical states [4, 5].”
Visvikis, D., Lambin, P., Mouridsen, K., Hustinx, R., Laßmann, M., Rischpler, C., Shi, K., & Pruim, J. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05891-w · Cited by 100
“One concerns the crea‐ tion of large, publicly available, open access image data‐ bases, such as for example ADNI or TCIA [77, 78], which preferably should be encouraged by public organisations.”
BackgroundEdmonds, E. C., Initiative, A. D. N., Delano‐Wood, L., Jak, A. J., Galasko, D. R., Salmon, D. P., & Bondi, M. W. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150986 · Cited by 98
“judgment, and a single impaired memory score to arrive at the diagnosis [1, 2].”
BackgroundNeuronal injury biomarkers and prognosis in ADNI subjects with normal cognition
Toledo, J. B., Weiner, M. W., Wolk, D. A., Da, X., Chen, K., Arnold, S. E., Jagust, W., Jack, C., Reiman, E. M., Davatzikos, C., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-26 · Cited by 89
Self-citationEdmonds, E. C., Weigand, A. J., Thomas, K. R., Eppig, J. S., Delano‐Wood, L., Galasko, D. R., Salmon, D. P., & Bondi, M. W. (2018) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617718000486 · Cited by 93
“Criteria for this classification were: (1) no subjective memory complaint; (2) MMSE score between 24 and 30; (3) global CDR of 0; (4) intact memory function based on delayed recall of Story A from the WMS-R Logical Memory II; and (5) no significant impairment in cognition or activities of daily living (Petersen et al.…”
InfluentialClinical performance and robustness evaluation of plasma amyloid‐β 42/40 prescreening
Rabe, C., Bittner, T., Jethwa, A., Suridjan, I., Manuilova, E., Friesenhahn, M. J., Stomrud, E., Zetterberg, H., Blennow, K., Hansson, O., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12801 · Cited by 88
Longitudinal changes in functional disability in Alzheimer's disease patients
Arrighi, H. M., Gélinas, I., McLaughlin, T. P., Buchanan, J., & Gauthier, S. G. (2013) · International Psychogeriatrics · doi:10.1017/s1041610212002360 · Cited by 89
Toledo, J. B., Bjerke, M., Da, X., Landau, S. M., Foster, N. L., Jagust, W., Jack, C., Weiner, M., Davatzikos, C., Shaw, L. M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4829 · Cited by 88
Self-citationDadar, M., Maranzano, J., Ducharme, S., Carmichael, O. T., DeCarli, C. S., Collins, D. L., & Initiative, A. D. N. (2017) · Human Brain Mapping · doi:10.1002/hbm.23894 · Cited by 84
Comparison of Automated Brain Volume Measures obtained with NeuroQuant® and FreeSurfer
Ochs, A. L., Ross, D. E., Zannoni, M. D., Abildskov, T. J., & Bigler, E. D. (2015) · Journal of Neuroimaging · doi:10.1111/jon.12229 · Cited by 88
Effect of Cognitive Reserve Markers on Alzheimer Pathologic Progression
Lo, R. Y., & Jagust, W. J. (2013) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3182900b2b · Cited by 94
Self-citationQuantitative structural MRI for early detection of Alzheimer's disease
McEvoy, L. K., & Brewer, J. B. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.162 · Cited by 90
Qiu, Z., Yang, P., Xiao, C., Wang, S., Xiao, X., Qin, J., Liu, C.-M., Wang, T., & Lei, B. (2024) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2024.3386937 · Cited by 95
Brain aging patterns in a large and diverse cohort of 49,482 individuals
Yang, Z., Wen, J., Erus, G., Govindarajan, S. T., Melhem, R., Mamourian, E., Cui, Y., Srinivasan, D., Abdulkadir, A., Parmpi, P., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03144-x · Cited by 102
Self-citationClinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD
Papp, K. V., Buckley, R. F., Mormino, E. C., Maruff, P. T., Villemagne, V. L., Masters, C. L., Johnson, K. A., Rentz, D. M., Sperling, R. A., Amariglio, R. E., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.09.074 · Cited by 85
Sørensen, L., & Nielsen, M. (2018) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.01.003 · Cited by 86
“The MMSE score was part of the information used to obtain the clinical diagnosis in ADNI (Petersen et al., 2010) whichin turn served as the label in the challenge.”
InfluentialMüller, S., Herde, L. D., Preische, O., Zeller, A., Heymann, P., Robens, S., Elbing, U., & Laske, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-40010-0 · Cited by 87
Artificial intelligence for clinical decision support in neurology
Pedersen, M., Verspoor, K. M., Jenkinson, M., Law, M., Abbott, D. F., & Jackson, G. D. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa096 · Cited by 94
“…to train a robust deep-learning model from scratch, so the authors deployed transfer learning to pre-train an AI model based on a previously acquired, and openly released, dataset that containing 921 subjects from the Alzheimer’s Disease Neuroimaging Initiative (Petersen et al. , 2010).”
MethodAssociations between Vascular Function and Tau PET Are Associated with Global Cognition and Amyloid
Albrecht, D., Isenberg, A. L., Stradford, J., Monreal, T. K., Sagare, A. P., Pachicano, M., Sweeney, M. D., Toga, A. W., Zloković, B. V., Chui, H. C., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1230-20.2020 · Cited by 87
Self-citationComparison of Feature Selection Techniques in Machine Learning for Anatomical Brain MRI in Dementia
Initiative, A. D. N., Tohka, J., Moradi, E., & Huttunen, H. J. (2016) · Neuroinformatics · doi:10.1007/s12021-015-9292-3 · Cited by 84
Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI
Holland, D., McEvoy, L. K., Dale, A. M., & Initiative, T. A. D. N. (2011) · Human Brain Mapping · doi:10.1002/hbm.21386 · Cited by 85
Memory is preserved in older adults taking AT1 receptor blockers
Initiative, A. D. N., Ho, J. K., & Nation, D. A. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0255-9 · Cited by 84
Heterogeneous cortical atrophy patterns in MCI not captured by conventional diagnostic criteria
Edmonds, E. C., Eppig, J. S., Bondi, M. W., Leyden, K. M., Goodwin, B., Delano‐Wood, L., McDonald, C. R., & Initiative, A. D. N. (2016) · Neurology · doi:10.1212/wnl.0000000000003326 · Cited by 87
Richard, E., Schmand, B. A., Eikelenboom, P., & Van Gool, W. A. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002541 · Cited by 84
Executive Dysfunction in MCI: Subtype or Early Symptom
Reinvang, I., Grambaitė, R., & Espeseth, T. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/936272 · Cited by 91
Familiarity-based memory as an early cognitive marker of preclinical and prodromal AD
Wolk, D. A., Mancuso, L., Kliot, D., Arnold, S. E., & Dickerson, B. C. (2013) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2013.02.014 · Cited by 84
Dimitriadis, S. I., Liparas, D., & Alzheimer's, D. N. I. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.233433 · Cited by 85
Association of fish oil supplement use with preservation of brain volume and cognitive function
Daiello, L. A., Gongvatana, A., Dunsiger, S., Cohen, R. A., Ott, B. R., & Initiative, A. D. N. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.02.005 · Cited by 89
Zhou, X., Qiu, S., Joshi, P. S., Xue, C., Killiany, R., Mian, A. Z., Chin, S., Au, R., Kolachalama, V. B., & Initiative, F. T. A. D. N. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00797-5 · Cited by 85
Verdi, S., Kia, S. M., Yong, K. X. X., Tosun, D., Schott, J. M., Marquand, A. F., Cole, J. H., & Initiative, T. A. D. N. (2023) · Neurology · doi:10.1212/wnl.0000000000207298 · Cited by 84
“29 The quality of raw scans was evaluated by University of California, San Francisco (UCSF) before our exclusion criteria.”
MethodScheller, E., Minkova, L., Leitner, M., & Klöppel, S. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00132 · Cited by 81
“Patients diagnosed with amnestic MCI are prone to convert to manifest Alzheimer’s disease (53, 54) and constitute the most studied subtype of MCI before the revised definition of prodromal AD was published (55–59).”
BackgroundRobust Identification of Alzheimer’s Disease subtypes based on cortical atrophy patterns
Park, J.-Y., Na, H. K., Kim, S. S., Kim, H., Kim, H. J., Seo, S. W., Na, D. L., Han, C. E., Seong, J., Initiative, A. D. N., et al. (2017) · Scientific Reports · doi:10.1038/srep43270 · Cited by 80
Self-citationMarks, J. D., Syrjanen, J. A., Graff‐Radford, J., Petersen, R. C., Machulda, M. M., Campbell, M. R., Algeciras‐Schimnich, A., Lowe, V. J., Knopman, D. S., Jack, C. R., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00944-y · Cited by 88
Self-citationGiacomo, S. D., Percaccio, E., Gullì, M., Romano, A., Vitalone, A., Mazzanti, G., Gaetani, S., & Sotto, A. D. (2022) · Nutrients · doi:10.3390/nu14183709 · Cited by 85
Samtani, M. N., Farnum, M. A., Lobanov, V. S., Yang, E., Raghavan, N., DiBernardo, A., Narayan, V. A., & Initiative, A. T. A. D. N. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011405497 · Cited by 81
Confirmatory factor analysis of the ADNI neuropsychological battery
Initiative, A. D. N., Park, L. Q., Gross, A. L., McLaren, D. G., Pa, J., Johnson, J. K., Mitchell, M. B., & Manly, J. J. (2012) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9190-3 · Cited by 84
Bangen, K. J., Weigand, A. J., Thomas, K. R., Delano‐Wood, L., Clark, L. R., Eppig, J. S., Werhane, M. L., Edmonds, E. C., & Bondi, M. W. (2019) · Neuropsychology · doi:10.1037/neu0000532 · Cited by 81
Tosun, D., Veitch, D. P., Aisen, P. S. S., Jack, C. R., Jagust, W. J., Petersen, R. C., Saykin, A. J., Bollinger, J., Ovod, V., Mawuenyega, K. G., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab008 · Cited by 86
“The diagnostic criteria for ADNI participants were described previously (Petersen et al., 2010).”
BackgroundSelf-citationThe A/T/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment
Ekman, U., Ferreira, D., & Westman, E. (2018) · Scientific Reports · doi:10.1038/s41598-018-26151-8 · Cited by 79
“p-tau** 33,19 (17,90) 27,62 (15,30) 32,30 (15,38) 28,56 (12,36) 45,05 (14,82) 34,72 (12,93) 42,79 (22,02) 39,89 (15,23)”
InfluentialSadikki, H., Fayossé, A., Cognat, E., Sabia, S., Engelborghs, S., Wallon, D., Alexopoulos, P., Blennow, K., Zetterberg, H., Parnetti, L., et al. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1003289 · Cited by 87
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration
Franzmeier, N., Suárez‐Calvet, M., Frontzkowski, L. K., Moore, A. M., Hohman, T. J., Morenas‐Rodríguez, E., Nuscher, B., Shaw, L. M. J., Trojanowski, J. Q., Dichgans, M., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00407-2 · Cited by 78
Self-citationWeiner, M. W., Veitch, D. P., Hayes, J., Neylan, T. C., Grafman, J. H., Aisen, P. S. S., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.005 · Cited by 81
Self-citationReduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment
Schott, J. M., Bartlett, J. W., Barnes, J., Leung, K. K., Sebastien Ourselin, A., & Fox, N. C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.011 · Cited by 82
“However, the ADNI dataset has been shown to be representative of patients who might be recruited for therapeutic studies (Petersen et al., 2010).”
Multiscale Neuroscience of Psychiatric Disorders
van den Heuvel, M. P., Scholtens, L. H., & Kahn, R. S. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.015 · Cited by 79
Accessible pediatric neuroimaging using a low field strength MRI scanner
Deoni, S., Bruchhage, M. M. K., Beauchemin, J., Volpe, A. R., D’Sa, V. A., Huentelman, M. J., & Williams, S. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118273 · Cited by 79
Schoemaker, D., Gauthier, S. G., & Pruessner, J. C. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9265-6 · Cited by 82
Ross, D. E., Ochs, A. L., Seabaugh, J. M., DeMark, M. F., Shrader, C. R., Marwitz, J. H., & Havranek, M. D. (2012) · Brain Injury · doi:10.3109/02699052.2012.694570 · Cited by 77
Traumatic brain injury and age at onset of cognitive impairment in older adults
Li, W., Risacher, S. L., McAllister, T. W., & Saykin, A. J. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8093-4 · Cited by 77
Franzmeier, N., Büerger, K., Teipel, S. J., Stern, Y., Dichgans, M., & Ewers, M. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.11.013 · Cited by 80
Elevated CNS Inflammation in Patients with Preclinical Alzheimer's Disease
Monson, N. L., Ireland, S. J., Ligocki, A. J., Chen, D., Rounds, W. H., Li, M., Huebinger, R. M., Munro Cullum, C., Greenberg, B. M., Stowe, A. M., et al. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.183 · Cited by 76
Benedet, A. L., Ashton, N. J., Pascoal, T. A., Leuzy, A., Mathotaarachchi, S. S., Kang, M. S., Therriault, J., Savard, M., Chamoun, M., Schöll, M., et al. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.08.002 · Cited by 75
Evaluation Methods and Measures for Causal Learning Algorithms
Cheng, L., Guo, R., Moraffah, R., Sheth, P., Candan, K. S., & Liu, H. (2022) · IEEE Transactions on Artificial Intelligence · doi:10.1109/tai.2022.3150264 · Cited by 88
Genome interpretation using in silico predictors of variant impact
Katsonis, P., Wilhelm, K. O., Williams, A. M., & Lichtarge, O. (2022) · Human Genetics · doi:10.1007/s00439-022-02457-6 · Cited by 86
An evolutionary explainable deep learning approach for Alzheimer's MRI classification
Shojaei, S., Abadeh, M. S., & Momeni, Z. (2023) · Expert Systems with Applications · doi:10.1016/j.eswa.2023.119709 · Cited by 82
“…’ s Disease Neuroimaging Initiative (ADNI) is an association consisting of Canadian and American universities and medical centers that aims to develop standardized imaging techniques and biomarker procedures for normal, mild cognitive impairment (MCI) and AD subjects (Petersen et al., 2010).”
Classifying Alzheimer's disease with brain imaging and genetic data using a neural network framework
Ning, K., Chen, B., Sun, F., Hobel, Z. B., Zhao, L., Matloff, W. J., & Toga, A. W. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.04.009 · Cited by 79
“…Alzheimer's Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu), a large dataset established in 2004 to measure the progression of healthy and cognitively impaired participants with brain scans, biological markers, and neuropsychological assessments (Petersen et al., 2010).”
BackgroundSelf-citationImportance of Treatment Status in Links Between Type 2 Diabetes and Alzheimer’s Disease
McIntosh, E. C., Nation, D. A., & Initiative, A. D. N. (2019) · Diabetes Care · doi:10.2337/dc18-1399 · Cited by 82
Bayesian latent time joint mixed effect models for multicohort longitudinal data
Li, D., Iddi, S., Thompson, W. K., Donohue, M., & Initiative, A. D. N. (2017) · Statistical Methods in Medical Research · doi:10.1177/0962280217737566 · Cited by 81
Self-citationA transformer-based unified multimodal framework for Alzheimer's disease assessment
Yu, Q., Ma, Q., Da, L., Li, J., Wang, M., Xu, A., Li, Z., & Li, W. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108979 · Cited by 87
Sacuiu, S. F., Insel, P. S., Mueller, S. G., Tosun, D., Mattsson, N., Jack, C. R., DeCarli, C. S., Petersen, R. C., Aisen, P. S. S., Weiner, M. W., et al. (2015) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.03.006 · Cited by 75
Self-citationTract-specific white matter hyperintensities disrupt neural network function in Alzheimer’s disease
Taylor, A. N. W., Kambeitz-Ilankovic, L., Gesierich, B., Simon-Vermot, L., Franzmeier, N., Araque Caballero, M. Á., Müller, S., Hesheng, L., Ertl-Wagner, B., Bürger, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.2358 · Cited by 73
Self-citationCai, S., Huang, L., Zou, J., JING, L.-L., Zhai, B., Ji, G., von Deneen, K. M., Ren, J., Ren, A., & Initiative, A. D. N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0115573 · Cited by 72
Guzman, V. A., Carmichael, O. T., Schwarz, C. G., Tosto, G., Zimmerman, M. E., Brickman, A. M., & Initiative, A. D. N. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.11.009 · Cited by 77
Xu, W., Initiative, A. D. N., Zhang, C. M., Li, J., Tan, C., Cao, X., Tan, L., & Yu, J. (2019) · Aging · doi:10.18632/aging.101971 · Cited by 74
Lim, Y. Y., Maruff, P. T., Schindler, R. J., Ott, B. R., Salloway, S., Yoo, D. C., Noto, R. B., Santos, C. Y., & Snyder, P. J. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.07.009 · Cited by 78
“This is due to (A) the very young age of participants enrolled in the study (on average 10 years younger than those enrolled in other cohorts) (Petersen et al., 2010; Rowe et al., 2013), and as such, we would not expect widespread neocortical amyloidosis in this very early preclinical stage, (B)…”
BackgroundDing, D., Zhao, Q., Guo, Q., Liang, X., Luo, J., Yu, L., Zheng, L., Hong, Z., & (SAS), S. A. S. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.03.004 · Cited by 74
Metadata
- Authors
- Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., Trojanowski, J. Q., & Weiner, M. W.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Neurology
- Published
- 2010-01-19
- Volume
- 74
- Issue
- 3
- Pages
- 201-209
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC2809036
- OpenAlex
- W2122328291
- Cited by
- 2,572
- References
- 27
- Citations by year
- 2026: 312 · 2025: 391 · 2024: 327 · 2023: 254 · 2022: 233 · 2021: 209 · 2020: 182 · 2019: 121 · 2018: 85 · 2017: 67 · 2016: 71 · 2015: 66 · 2014: 45 · 2013: 63 · 2012: 59
- FWCI
- 26.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (submittedVersion)
- PubMed Central (submittedVersion)
- Funders
- Alzheimer's Disease Neuroimaging Initiative (AG024904)
- National Institutes of Health (5r01ag027984-03, 5r01ag030048-05, n01mh22005-16-0-1, 5r01dk075128-05, 5u01ag006786-38, 5r01mh083552-05, 5r01ca104573-05, 5p30ag010124-30, 5p01ag009215-20, 5r01ag011378-25, 5p41rr023953-04, 5u01ag024904-10, 5u01ag029213-05, 5r01ag016381-08, 5r01eb006266-04, 5r01ag010897-27, AG024904, 5p01ag019724-23, 5p30ca093373-23, 5p50ag016574-20)
- National Institute on Aging (AG027984, U01-AG-024904, R01AG11378, P30AG010129, U19 AG010483, U01‐AG10483, R01-AG030048, P50‐AG16574, P01 & AG019724, U01AG06786, P50-AG23501, RC1AG035427, AG 010483, R01AG031224, AG031224, P01 AG 17586-10, 1 U01 AG024904, AG 024904, UO1AG029213-01, P30AG036468, 2 P50 AG016570, 1 U01 AG 024904-05, P30 AG 10124-18, R01 AG031252, P01AG017586, U01AG010483, 1 U01 AG24904, 1P01 AG-19724-07, R01AG027859, P50AG023501, AG027859, P01 AG012435, AG-11378, 2P50AG005133, RC2AG036535, P01-AG19724, P01 AG 09215-20, R01-AG 10897, 2P30AG10129, R01 AG029672, R01 AG16381)
- National Heart, Lung, and Blood Institute (HL-095089, R01HL095089)
- National Institute of Mental Health (U01MH083506, MH 22005, MH062512, MH083506, R01MH079752, R01MH069433, MH083552, MH079752, R01 MH069259, 5 R01 MH071940, MH069433, R01MH072641, P30MH062512)
- National Institute on Drug Abuse (1 R01 DA017830)
- National Cancer Institute (2 P30 CA93373, CA104573)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK075128)
- National Institute of Neurological Disorders and Stroke (1 R01 NS050792, RL1NS062412, P50NS053488, 1 R01 NS049194, RC2NS069368, R01NS031966)
- National Institute of Biomedical Imaging and Bioengineering (1 U54 EB05149, 1 R01 EB 006266-01, U54EB005149, P01EB001955, 5R01EB002138-07)
- U.S. National Library of Medicine (2 R01LM005639)
- National Center for Research Resources (5 P41 RR013642, P41 RR-023953, U24RR021760, U54RR021813, R24 RR021382, R24 RR021992, KL2RR024144)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD050735, 1R01 HD053893-01)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, mild cognitive impairment, neuroimaging biomarkers, cerebrospinal fluid biomarkers, amyloid-beta 42, longitudinal cognitive change, normal aging, memory impairment, ADAS-Cog
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cross-Sectional Studies, Diagnostic Imaging, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
